AmnioChor, Inc., a Chicago, IL-based early stage biotech startup based on perinatal stem cell technology, received a seed funding of undisclosed amount.
Backers included the Musculoskeletal Transplant Foundation of Edison NJ.
The company intends to use the funds for the development of the proprietary AmnioCept™ product line and OmniBank placental tissue storage capabilities.
Led by Russ Schweizer, CEO, AmnioChor has developed technology that allows cryopreservation of the amniotic membrane of the placenta, and the human stem cells living within those tissues.
The company’s products are intended to augment umbilical cord blood, and will additionally contain Epithelial and Mesenchymal stem cells that may be used in technologies including 3-D printing of human organs.
FinSMEs
02/08/2015